Thymalin is a calf thymus-derived peptide complex used for immune support, T-cell stimulation, and anti-aging. It has no FDA-approved indication, so all human use is off-label or compounded, and the exploratory human research is thin and mostly without posted results. Community posters report doses from 500 µg to 10 mg, most commonly 10 mg daily, and one clinician protocol lands in the same place: 10 mg daily by intramuscular injection. The honest tradeoff to keep in mind is that the evidence base is thinner than the surrounding discussion suggests.
Data last updated
Measured on 5 of 6 axes
Evidence shape
Thymalin possesses a low tier of evidence, supported only by two exploratory human treatment studies. While the literature includes preclinical research on its mechanisms, there are zero registered clinical trials and no completed, large-scale studies to validate its efficacy. This lack of formal trial data means the current evidence base remains thin and restricted to early-stage observations, leaving the peptide without the rigorous, blinded human testing required to establish clinical standards.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Treatment studies
2 studies
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How THYMALIN is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Two published human studies were identified, but dosing information was not reliably extracted. Therefore, no specific amount, frequency, or cycling can be summarized for this tier.
In this tier, the reported dose is a fixed 10 mg given by intramuscular injection once daily, with no cycling protocol specified.
Users dose Thymalin daily, typically around 10 mg with a reported range of 400 µg to 10 mg per dose, though some reports did not specify a schedule.